Vertex non-opioid painkiller shows positive results in critical late-stage trial on acute pain
Publishing timestamp: 2024-01-30 16:31:25
Summary
Vertex Pharmaceuticals' experimental painkiller, VX-548, significantly decreased post-surgery pain in late-stage trials. However, it did not work better than the popular opioid. The trial results bring the biotech company closer to developing a drug that can provide strong pain relief without the addictive potential of opioids. Vertex plans to file for FDA approval of the painkiller by the middle of this year.
Sentiment: MIXED
Tickers: CRSP, VRTX, .AD.IXIC,
Keywords: health care industry, business, science, biotech and pharmaceuticals, biotechnology, vertex pharmaceuticals inc, united states, crispr therapeutics ag, business news, pharmaceuticals,